Research Article |
Corresponding author: Asmaa Abdelaziz Mohamed ( asmaa.abdelaziz@alzahraa.edu.iq ) Academic editor: Denitsa Momekova
© 2023 Asmaa Abdelaziz Mohamed, Noor Zuhair Kbah, Osama N. Wennas.
This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Citation:
Mohamed AA, Kbah NZ, Wennas ON (2023) Poly (lactic-co-glycolic acid) nanoparticles for drug delivery of rupatadine fumarate: development and evaluation. Pharmacia 70(4): 1257-1264. https://doi.org/10.3897/pharmacia.70.e110191
|
This study aimed to consolidate rupatadine fumarate (RF) into nanoparticles to control its release. Ten RF nanoparticles were developed by nanoprecipitation using poly (lactic-co-glycolic acid) (PLGA) , polyvinyl alcohol (PVA), and Poloxamer 407 (Kolliphor P 407) in different percentages. A valid reverse-phase HPLC method was developed to assess RF in the formulated nanoparticles. The RF nanoparticles were tested chemically and morphologically. RF nanoparticles containing PLGA and PVA and Kolliphor P 407 have zeta potentials ranging from -24.4 mV±0.24 to -26.7 mV±0.05, higher than other formulations, and their release profiles were optimised. The formula (RPX3) had the best zeta potential (-26.7 mV±0.05), released about 86% of RF after 8 h and extended for 24 h. In summary, the formulation (RPX3), including 2:10:3:1.5 ratios of the drug PLGA: PVA: Kolliphor P 407 was the optimised RF-loaded nanoparticles formulation.
controlled release, HPLC, nanoprecipitation
Rhinitis allergies (AR) are a global health condition affecting approximately 400 million people globally. Increased urbanisation and environmental contaminants are believed to be the primary factors in AR’s increasing incidence over the years. Therefore, comprehending the pathophysiology of AR is crucial to the development of innovative therapies for this illness, which usually coexist with other respiratory disorders (
Nanoparticles (NPs) can increase the safety and efficacy of drugs, improving stability and bioavailability (
PLGA has numerous biomedical uses due to its biodegradability and bioavailability (
Although RF time to maximum plasma concentration (Tmax) ranged from 45 min to 1 h post-oral administration, its half-life is 4.6 h (
In our current investigation, we formulated ten RF nanoparticles by nanoprecipitation with PLGA, PVA, and Kolliphor P 407 to achieve sustained release over 24 h to overcome fluctuations in RF plasma concentration. Compatibility tests were performed to ensure the absence of undesired interactions. The microencapsulation parameters were assessed, and the nanoparticles were characterised. Moreover, the optimum nanoparticle formulation was morphologically assessed.
Rupatadine fumarate (HPLC, 98.3%) and polyvinyl alcohol (Mw 90,000) were purchased from Sigma-Aldrich, USA. PLGA was purchased from Evonik Corporation, USA. Kolliphor P 407 was purchased from BASF, Germany. Methanol and acetonitrile for HPLC; E. Merck, Darmstadt, Germany. Hydrochloric acid, acetone, and sodium hydroxide pellets; Schuarlo, Spain.
The system components included an Agilent HPLC model HP 1260 instrument employing an Agilent 1260 photodiode array detector, a Zorbax C18 (5 μm, 25 cm × 4.6 mm) column, and 0.05 M potassium monobasic phosphate (pH 3): methanol: acetonitrile in the ratio 20:60:20 as the mobile phase. RF was assessed at 243 nm, and 50 ul was injected.
The validation was performed following the ICH Harmonisation Guideline: Validation of Analytical Techniques (Q2 R1) (
Five injections of a standard solution with a concentration of 100% were used to evaluate its appropriateness. Its properties were obtained using an HPLC apparatus (Agilent). The parameters such as theoretical plates, tailing factor, retention time, resolution, and analyte peak area were assessed and should meet the FDA’s standards for acceptability (
In the range of 4–20 μg/mL, we assessed RF. After constructing the standard curve, the slope, y-intercept, and coefficient (R2) were obtained, where linearity is the capacity to acquire results directly proportional to the RF concentration, and the average area (mAu*sec) was plotted against concentrations. R2 should be greater than 0.998 as proof of an appropriate fit.
Accuracy indicates the closeness between anticipated and actual values. Three consecutive analyses (n = 3) were conducted in triplicate at three distinct concentrations (10.24 µg/mL, 12.8 µg/mL, and 15.36 µg/mL). The acceptable mean recovery falls within the range of 90–100%. Then, spiking using an additional percentage of RF and the accuracy of the recovered amount was determined.
We investigated repeatability and precision at the intermediate level of the HPLC method for RF using six analyses of the test concentrations. Six concentrations were measured by three separate analysers to emphasise intermediate accuracy, and the %RSD was calculated. Precision is the degree of agreement between individual tests when applied repeatedly on three separate occasions to analyse multiple replicates. The intraday precision was determined by analysing six replicates with varying RF concentrations measured on the same day. Six replicates of various RF concentrations were analysed on three separate days to determine the interday precision.
Specificity aimed to demonstrate the ability to distinguish the principal peaks from the placebo and all related substances to confirm no interference from the excipients in the formulations.
The lowest strength of RF that can be detected but not quantified is known as the LOD, and the lowest strength of RF that can be measured precisely enough is known as the LOQ. LOD = 3.3 × SD/S and LOQ = 10 × SD/S were employed to calculate these two parameters, where SD = standard deviation and S = slope of the standard curve.
Robustness is the capacity to remain unaffected by slight parameter variations and to attain analysis reliability. Robustness was evaluated by analysing the impact of variations, such as wavelength and flow rate.
Composition* | Formulation | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
RPP1 | RPP2 | RPP3 | RPP4 | RPP5 | RPX1 | RPX2 | RPX3 | RPX4 | RPX5 | |
PLGA | 0.25 | 0.5 | 0.75 | 1 | 1.5 | 0.25 | 0.5 | 1 | 1 | 1.5 |
PVA | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 | 0.1 | 0.2 | 0.3 | 0.4 | 0.5 |
Kolliphor P 407 | – | – | – | – | – | 0.05 | 0.1 | 0.15 | 0.2 | 0.3 |
Acetone | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Water | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Base hydrolysis was done by adding 2 mL of 1M NaOH, followed by boiling for about 15 min, cooling, neutralising through the addition of 0.1 M HCl using a pH meter, and completing 100 mL with 0.1 M HCL, diluted with water, and injected into HPLC. Acid hydrolysis was performed by dissolving 5 mL of 0.5 M HCl in a conical flask, then boiling for ¼ h, cooling, and neutralising with 0.1 M NaOH using a pH meter, diluting with water, and injecting the solution into HPLC. Oxidation was performed by hydrogen peroxide after standard dissolving in 2 mL of 1 M HCL, 5 mL of 30% H2O2 solution was added, mixed, then boiled in a water bath for 15 minutes, cooling, diluting with water, and injecting the solution into HPLC.
100 mg of the drug and PLGA were solubilised in 25 mL of acetone and sonicated on an ultrasonic (Elma, Germany) for 5 minutes to dissolve RF and polymer. This solution was injected into 25 mL of PVA or mixed with Kolliphor P-407 solution to make a suspension. The suspension was broken up into nanoparticles by homogenisation at 25000 rpm (GLH 850 Laboratory Homogenizer, USA), moved to a magnetic stirrer (IKA magnetic stirrer, Germany), and stirred until the organic phase completely evaporated to make a colloidal suspension of PLGA-NPs. The suspension was dried in a vacuum dryer overnight, and the nanoparticles were collected.
The particle size (PS), the polydispersity index (PDI), and the zeta potential (ZP) of the NPs were assessed at 25 °C employing a Zetasizer (Malvern Instruments, Malvern, UK) and dynamic light scattering (DLS) in triplicate. ZP was obtained by placing samples post-dispersion in distilled water (
The centrifugation method was employed to calculate RF’s content and entrapment efficiency. Nanoparticle powder (including RF equivalent to 10 mg) was dispersed in 5 mL acetonitrile and centrifuged at 20000 rpm for ½ h in a centrifuge (BOECO Centrifuge SC-8, Germany) to separate the supernatant. Then, the concentrated liquid was filtered, and the drug concentration was estimated. The following equations were used to determine the content and entrapment efficiency (
The compatibility of RF with used polymers and its effect on their functional groups was assessed. The spectrum showed characteristic absorptions related to O-H, C=C, and C-H bonds stretching at 3491, 3050, and 2882 cm-1, respectively. Moreover, the absorption band of 1705 cm-1 corresponds to the carbonyl groups (C=O). C=N bending at 1432 cm-1, and finally, C-CL bending at 851 cm-1. These findings are similar to previous literature on characteristic peaks of RF (
The release of RF from formulations that do not include Kolliphor P 407 is shown in Fig.
The morphology of the RF-NPs was scanned, and particle diameter and shape were assessed employing transmission electron microscopy (TEM) (Wilson et al. 2021). After appropriate dilution, a drop of the RF-NPs formulation was introduced onto a grid, and the image was examined via JEM-1400, JEOL (Tokyo, Japan).
We employ one-way analysis of variance (ANOVA) to determine the p-value of linearity.
Linearity and range
A new HPLC method was invented and validated to analyse RF, including validation parameters per ICH and USP guidance (
Acceptance criteria | Results | |
---|---|---|
Linearity | Correlation coefficient R2 ≥ 0.98 | 0.9988 |
Slope | 50.831 | |
Intercept | 32.504 | |
Regression equation | 50.831x + 32.504 | |
p-value lower than 0.05 | 0.025 | |
Accuracy | Mean% recovery | 99.7% |
(95% to 105%) | 0.36% | |
RSD ≤ 2% | ||
Precision | Repeatability (RSD% ≤ 5%) | 0.15% |
Intermediate precision (RSD% ≤ 10%) | 0.31% | |
Sensitivity | LOD | 0.667 µg/mL |
LOQ | 2.022 µg/mL | |
Forced degradation | Recovery% in 1 M HCl | 87.91% ± 0.39 |
Recovery% in 1 M NaOH | 92.17%± 0.11 | |
Recovery% in 10% H2O2 | 90.47% ± 0.25 | |
Robustness | RSD% at a flow rate of 1.2 mL/min | 0.31% |
RSD% at a flow rate of 0.8 mL/min | 0.29% | |
RSD% at pH 2.8 | 0.16% | |
RSD% at pH 3.2 | 0.35% |
The method’s high specificity was determined by analysing a placebo and a standard solution; no peak was detected near the retention time of RF, indicating its high specificity.
The R2 obtained was 0.9991 within the limits (not less than 0.99), the intercept was 33.524, and the p-value was 0.026. The method was accurate; the recovery ranged from 99.3% to 100.4%. Furthermore, the RSD values were less than 1% or complied with the limit of <2%, indicating that the method was precise based on close assessments of the same sample. The method’s sensitivity was emphasised by calculating the LOD and LOQ for RF to be 2.05 µg/mL and 6.2 µg/mL, respectively. The specificity was proved by injecting a placebo, and no peaks appeared in the RF-retention time. Degradation of RF in 1M HCl, 1M NaOH, and 10% H2O2 was 7.83%, 12.09%, and 9.53%, respectively. Furthermore, the method was robust, as the RSD did not exceed 0.3% with slight variation. The results are shown in Table
Table
Formula | Drug Content* (%) ± SD | Efficiency entrapment (%) ± SD | Zeta Potential* (mV) ± SD | Mean particle size* (nm) ± SD | PDI* |
---|---|---|---|---|---|
RPP1 | 61±0.21 | 86.31±0.15 | -21.9±0.09 | 388.0 ±1.7 | 0.41±0.01 |
RPP2 | 65±0.13 | 80.02±0.31 | -23.8±0.19 | 457.2±1.6 | 0.54±0.02 |
RPP3 | 63±0.11 | 81.00±0.26 | -22.2±0.07 | 547.1±1.3 | 0.62±0.01 |
RPP4 | 59±0.31 | 85.78±0.30 | -24.1±0.05 | 467.2±1.8 | 0.49±0.02 |
RPP5 | 57±0.27 | 83.14±0.32 | -21.7±0.27 | 428.0±0.9 | 0.48±0.01 |
RPX1 | 67±0.28 | 88.12±0.13 | -25.3±0.13 | 352.0±1.1 | 0.48±0.02 |
RPX2 | 68±0.14 | 85.19±0.12 | -24.4±0.24 | 447.3±1.3 | 0.42±0.01 |
RPX3 | 69±0.18 | 89.14±0.16 | -26.7±0.05 | 415.0±2.4 | 0.37±0.01 |
RPX4 | 67.3±0.17 | 81.7±0.24 | -26.1±0.11 | 379.4±1.2 | 0.37±0.02 |
RPX5 | 71.9±0.24 | 79.56±0.19 | -25.1±0.02 | 574.3±1.1 | 0.47±0.01 |
The RF content of RPP1 to RPP5 nanoparticles ranged from 57%±0.27 to 65%±0.13 and the entrapment efficiency ranged from 80.02 ±0.31 to 86.31±0.15 while RPX1 to RPX5 nanoparticles (containing Kolliphor P 407) content uniformity and entrapment were 67.3±0.17 to 71.9 ±0.24 and 79.56 ± 0.12 to 89.14±0.16, respectively, as shown in Table
The compatibility of RF with used polymers and its effect on their functional groups was assessed. The spectrum showed characteristic absorptions related to O-H, C=C, and C-H bonds stretching at 3491, 3050, and 2882 cm-1, respectively. Moreover, the absorption band of 1705 cm-1 corresponds to the carbonyl groups (C=O). C=N bending at 1432 cm-1, and finally, C-CL bending at 851 cm-1. These findings are similar to previous literature on characteristic peaks of RF (
The release of RF from formulations that do not include Kolliphor P 407 is shown in Fig.
Based on the results mentioned, the formulation RPX3 was chosen for more research because the nanoparticles were about 415 nm in size, the zeta potential was -26.7 mV, and the best release was 86% after 8 hours. Fig.
Many researchers used PLGA to modify the release of some drugs. For instance,
The incorporation of RF into nanoparticles employing PLGA, PVA, and Kolliphor P 407 through nanoprecipitation resulted in enhanced characteristics, including optimal production yield, high drug content, exceptional drug entrapment efficiency, and sustained release to avoid fluctuation in RF plasma concentration. Therefore, NPs containing PLGA, PVA, and Kolliphor P 407 can be alternatives to the current conventional dosage forms for the delivery of RF with improved properties and bioavailability.
The authors appreciate Al-Zahraa University for women support.